This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Advanced Focus Stack
Heavy Stack / Locked-In Focus / Cortical Communication / Experienced Researchers
Overview
What is Advanced Focus Stack?
Sean's 'Advanced' tier focus stack — six research compounds layered to optimize cognition itself rather than just stimulate wakefulness. Combines a foundational cholinergic anchor (CDP-Choline), an AMPAR positive allosteric modulator (TAK-653), a multi-mechanism racetam (Nefiracetam), an M1/Sigma-1 dual agonist (AF710B), a long-arc neuroplasticity restorer (NSI-189), and a sensory-gating filter (Tropisetron). All compounds are Research Use Only and intended for experienced researchers, not entry-level use.
Key Benefits
Targets glutamatergic signaling, cortical communication, synaptic plasticity, dopamine synthesis/release, cholinergic efficiency, sensory gating, neuroplasticity pathways, and long-term potentiation (LTP). Researchers report sustained attention, enhanced working memory, cleaner mental organization and verbal fluidity, smoother information processing, improved encoding/recall, and resistance to cognitive fatigue. Effects compound: TAK-653 + Nefiracetam drive acute glutamatergic and cholinergic gains; NSI-189 + AF710B drive long-arc structural neuroplasticity; CDP-Choline supports the rising acetylcholine demand; Tropisetron filters noise.
Mechanism of Action
Multi-pathway convergence on cognition. CDP-Choline supplies choline + cytidine for acetylcholine synthesis and phospholipid membrane repair. TAK-653 selectively potentiates AMPA receptors only when glutamate is already active, amplifying normal glutamatergic transmission and BDNF/ERK/Akt/mTOR/p70S6K signaling. Nefiracetam potentiates α4β2 nicotinic receptors, modulates NMDA glycine-site signaling, PKC pathways, voltage-gated calcium channels, GABA, and reduces NMDA magnesium block. AF710B combines allosteric M1 muscarinic agonism with Sigma-1 agonism, potentiating ERK/CREB and rescuing synaptic spine loss. NSI-189 modulates the TLX nuclear receptor driving hippocampal neurogenesis and increases hippocampal volume. Tropisetron antagonizes 5-HT3 while partially agonizing α7 nicotinic receptors, improving signal-to-noise in cortical processing.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.